Tadalafil Tablet, Film Coated
Product Images NDC 72789-344

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72789-344). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789344 Label (72789344)

Label for Tadalafil USP 20 mg oral film-coated tablets, packaged with 15 tablets per container. The label includes the NDC 72789-344-15 and is marked as a prescription drug by PD-Rx Pharmaceuticals, Inc. The label shows dosage instructions spaces, batch lot H23B21, and expiration date 01/2026. It includes warnings about keeping out of reach of children and directs users to the package insert for dosage and storage.*

FDA Label Image

Chemical Structure (Tadalafil 1)

Chemical structure of Tadalafil, the active ingredient in the product tadalafil 20 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc. The diagram shows the molecular arrangement of atoms and bonds characteristic of Tadalafil.*

FDA Label Image

Tadalafil-tablets-figure-1 (Tadalafil 2)

Four line graphs comparing blood pressure differences (tadalafil minus placebo) over time, measured in hours. The graphs show standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with y-axes indicating difference in mmHg and x-axes representing time from 0 to 96 hours.*

FDA Label Image

Tadalafil-tablets-figure-2 (Tadalafil 3)

Two line graphs comparing the effects of tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over 24 hours. The top graph shows standing systolic blood pressure, and the bottom graph shows supine systolic blood pressure, both measured in mmHg over time post-dose in hours.*

FDA Label Image

Tadalafil-tablets-figure-3 (Tadalafil 4)

A line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil plus 8 mg doxazosin or placebo plus 8 mg doxazosin at 08:00 and 20:00. The graph includes four lines representing different treatment times and conditions, illustrating blood pressure trends post-dose.*

FDA Label Image

Tadalafil-tablets-figure-4 (Tadalafil 5)

A pharmacokinetic line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing following 5 consecutive days. Error bars represent variability at each time point over 120 hours.*

FDA Label Image

Table 5 (Tadalafil 6)

Line graph depicting the change from baseline in IPSS Total Score over a 12-week treatment duration, comparing Tadalafil 5 mg with placebo. The graph shows greater score reduction with Tadalafil 5 mg than placebo at 4, 8, and 12 weeks, with statistical significance noted (p<0.01).*

FDA Label Image

Table 6 (Tadalafil 7)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change from baseline in IPSS score. Tadalafil shows a greater decrease in score compared to placebo throughout the study period, with statistical significance indicated at p<0.01.*

FDA Label Image

Tadalafil-tablets-figure-7 (Tadalafil 8)

A line graph depicting least squares mean change from baseline over weeks of therapy (0, 4, 12, 26) comparing Tadalafil/Finasteride and Placebo/Finasteride. The graph shows a decrease in mean change from baseline for both groups, with markers indicating statistical significance at various points (p<0.001, p<0.05).*

FDA Label Image

Image 8 (Tadalafil 9)

A line graph depicting the change from baseline in IPSS Total Score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the score change. Tadalafil shows a greater score reduction than placebo, with statistical significance indicated (p<0.01).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.